Anzeige
Mehr »
Mittwoch, 08.10.2025 - Börsentäglich über 12.000 News
Defence-Aktie mit Ritterschlag: Regierungs-Einladung zur größten Militärmesse
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 919473 | ISIN: US8269171067 | Ticker-Symbol:
NASDAQ
08.10.25 | 21:57
8,280 US-Dollar
-2,13 % -0,180
1-Jahres-Chart
SIGA TECHNOLOGIES INC Chart 1 Jahr
5-Tage-Chart
SIGA TECHNOLOGIES INC 5-Tage-Chart

Aktuelle News zur SIGA TECHNOLOGIES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14.09.SIGA To Appeal $1.175 Million FINTRAC Fine4
12.08.SIGA Technologies - A solid quarter for topline growth413Q225 was a strong quarter for SIGA, supported by material topline traction, with deliveries of $79m of oral and IV TPOXX to the US strategic national stockpile (SNS), fully servicing the order book...
► Artikel lesen
06.08.SIGA advances pediatric and PEP programs as product revenues reach $79M, supported by new BARDA funding8
SIGA TECHNOLOGIES Aktie jetzt für 0€ handeln
05.08.SIGA TECHNOLOGIES INC - 10-Q, Quarterly Report-
05.08.SIGA TECHNOLOGIES INC - 8-K, Current Report3
29.07.SIGA Technologies Inc.: SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results2
24.06.SIGA Reports Record Profits for Latest Fiscal Year5
12.06.SIGA TECHNOLOGIES INC - 8-K, Current Report1
15.05.Dividendenbekanntmachungen (15.05.2025)17.843 Unternehmen  ISIN-Code  Dividende (Währung)  Dividende (EUR)  1&1 AG  DE0005545503 - 0,05 EUR  A10 NETWORKS INC  US0021211018  0,06 USD  0,0536 EUR  ADMIRAL GROUP PLC  GB00B02J6398  0,914 GBP  1,0846...
► Artikel lesen
13.05.SIGA Technologies - Another strong period for the order book685Q125 marked another active period for SIGA's order book, with BARDA exercising the final $26m intravenous (IV) TPOXX option in March, expected to be delivered in 2026, consistent with our estimates....
► Artikel lesen
08.05.SIGA TECHNOLOGIES INC - 10-Q, Quarterly Report-
08.05.Investition von 40 Mio. Euro in Halberstadt: SIGA baut Produktionswerk21
01.05.SIGA Technologies Inc.: SIGA to Host Business Update Call on May 8, 2025 Following Release of First-Quarter 2025 Results2
29.04.Dividendenbekanntmachungen (29.04.2025)12.514 Unternehmen  ISIN-Code  Dividende (Währung)  Dividende (EUR)  361 DEGREES INTERNATIONAL LTD  KYG884931042  0,1 HKD  0,0112 EUR  ACOMO NV  NL0000313286 - 0,85 EUR  ACOMO NV  NL0000313286 - 0,85 EUR  ACROW...
► Artikel lesen
10.04.SIGA Technologies - Dividends bring cheer amid market uncertainty582SIGA Technologies has declared a special dividend of $0.6 per share, marking a fourth straight year of dividend declarations. The outlay is at a similar level to the one paid in March 2024 ($43m based...
► Artikel lesen
19.03.SIGA Technologies - Entering a crucial period for business outlook526SIGA Technologies reported another year of top-line growth in FY24, with performance weighted to Q4, driven by material TPOXX deliveries to both domestic and international markets. Product revenue grew...
► Artikel lesen
11.03.SIGA Technologies Inc.: SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2024291Increased Product Sales to $133 Million in 2024Generated Pre-tax Operating Income and Net Income of $70 Million and $59 Million, Respectively, in 2024Corporate Update Conference Call Today at 4:30...
► Artikel lesen
02.01.SIGA Technologies Inc.: TEPOXX (tecovirimat) Approved in Japan for the Treatment of Orthopoxviruses531Regulatory decision marks first approval in Japan of an antiviral for the treatment of orthopoxviruses including smallpox, mpox and cowpoxJapan Biotechno Pharma Co., Ltd. engaged as exclusive distributor...
► Artikel lesen
10.12.24SIGA Technologies Inc.: Interim Results from STOMP Study of SIGA's Tecovirimat in Treatment of Mpox Announced318Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate clade II mpoxStudy stopped enrolling patients in all study armsResults...
► Artikel lesen
19 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1